SOPHiA GENETICS SA

Good day, and thank you for standing by. Welcome to the Sophia Genetics Third Quarter 2021 Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker presentation, there will be a question-and-answer session. To ask a question during a session, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I want to ask you to have a conference over to your speaker today, Alexander Kahn, Investor Relations. Please go ahead.

Thank you. Earlier today, Sophia Genetics released financial results for the quarter ended September 30th, 2021. If you hadn't received this news release, or if you'd like to be added to the company's distribution list, please send an email to ir at sophiagenetics.com. Joining me today from Sophia Genetics are Yurgy Kamlong, co-founder and CEO, Ross Muecken, Chief Financial Officer, Laura Hashimoto, Chief Business Officer, and Philippe Manou, Chief Medical Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of U.S. federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section titled Cautionary Statement Regarding Forward-Looking Statements in Exhibit 99.2 of the report on Form 6K on file with the SEC. Except as required by law, Sophia Genetics disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as it is broadcast November 10th, 2021. With that, I would like to turn the call over to Yurgi.

Thank you, Alex, and good morning, everyone. I'm excited to be here today. and welcome you all as we continue on our journey as a public company. On today's call, I will start with an overview of our progress during the quarter under the framework of our five pillars as it relates to network development and platform usage, after which we will hear from Lara regarding our money expansion. Next, I will discuss in more detail various partnerships and relationships which we are excited about. Finally, I will walk through our goals and objectives for the balance of the year and beyond. I will then turn the call over to Ross for a more detailed look at our third quarter financial results and our outlook for the remainder of 2021. To further expand and leverage the power for our platform, we remain focused on the five key objectives we have previously highlighted. First, expanding customer adoption with new clinical customers especially in the United States. Second, increasing utilization within our existing clinical customer base. Third, further advancing our platform through continued innovation to increase its capabilities and broaden its application. Fourth, developing partnerships and collaborations across the healthcare ecosystem. And fifth, leveraging our platform and database to continue to drive adoption with biopharmaceutical companies. Starting with a new customer adoption, during the third quarter, our total customer base continued to grow, now including over 780 customers globally. We're especially focused on growing the adoption of our platform in the U.S. market, which we view as our largest addressable market opportunity. Additionally, we are very excited and encouraged by the size and scale of our new customer relationships. In the U.S., we recently signed an agreement with City of Hope, a national leader in cancer care, to expand their use of our technology to include a more comprehensive solution for cancer research that will advance analytical performance. Utilizing SOFIA BBM for TSO500, City of Hope plans to upgrade the quality of molecular research capabilities to ultimately benefit thousands of patients. Our platform will allow City of Hope to report expert bioinformatics in one easy-to-use workflow, including somatic tumor analysis, expanded variant, NCND coverage, and more. Our intent is to help elite institutions like City of Hope and labs of all sizes around the world expand the scope of their cancer research with our ability to simplify the process without sacrificing the quality of the results. As we have previously highlighted, Our broad offerings at SOFIA provide value to any customer in oncology using TSO500. As we continue to expand our presence and offerings, we are achieving great traction within the U.S., where we are penetrating a highly centralized market. As a partner of choice, we also remain independent in our approach to establishing valuable relationships within the industry. Our expectation is that City of Hope will be just one example demonstrating the strong value proposition that SOFIA brings to the market as our platform capitalizes on the industry trend of decentralization. In the EMEA region, we also recently signed a multi-year agreement with RCT Gustave Roussier to support their data analytic initiatives, further underscoring our ability to obtain expanded usage through existing relationships. Institut Gustave Roussy is one of the largest cancer treatment centers in Europe and is considered among the top specialized hospitals in the world, along with such prominent names as the Mayo Clinic and Dana-Farber Cancer Institute in the U.S. In addition, we see similar dynamics in other geographies around the world. For instance, we have signed a compelling deal in the APAC region to support the decentralized usage of liquid biopsy testing. As the transition toward decentralization is ongoing, we are now seeing this not only in hereditary and solute tumor testing, but incrementally as it relates to liquid biopsy as well. Altogether, we endeavor to expand our base of relationships with additional agreements, and in conjunction with the opportunity to bridge one with another, we see menu expansion further increasing the size of the network, as Lara will discuss in more detail later. Moving on to our second objective regarding the utilization of our platform, we employ a land and expand commercial model that is focused on winning new customers and then driving greater utilization of our solution by those customers. Once we have secured the customer, we use our direct sales force to build further engagement and help that customer profitably increase testing operations. We also target additional clinician users and departments within each institution. During the third quarter, total recurring platform customers grew from 367 customers in the second quarter of this year to 375 customers, and the total number of analysis for the quarter was approximately 62,000. This strong year-on-year momentum is underpinned by growing demand from new customers as well as existing customers, broadening their usage to growing number of applications. We're also excited about our momentum in North America. In the third quarter, regional platform analysis volume grew 67% year-on-year and 11% quarter-over-quarter. During the quarter, we also added several key customers in the region. Now, shifting to our third objective related to money expansion, I will turn the call over to Lara Shimoto to discuss some exciting developments in further detail. Lara?